Denali Therapeutics(DE:4DN)
€17.95+-0.29 (+3.01%)
DE:4DN
Denali Therapeutics financials statements
€17.95
At close:+-0.29 (+3.01%)
Denali Therapeutics (4DN) Income Statement
7 Followers
Denali Therapeutics Income Statement
Last quarter (Q3 2026), Denali Therapeutics's total revenue was $17.78M. In Q3, Denali Therapeutics's net income was $70.13M. See Denali Therapeutics’s key income statements, including revenue, expenses, profit, and income.
| Income Statement | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| $ 0.00 | $ 0.00 | $ 330.53M | $ 108.46M | $ 48.66M | |
| $ -11.18M | $ 0.00 | $ 330.53M | $ 108.46M | $ 48.66M | |
| $ 544.16M | $ 487.34M | $ 527.23M | $ 449.21M | $ 344.41M | |
| Depreciation and Amortization | $ 14.81M | $ 8.99M | $ 16.73M | $ 10.38M | $ 8.59M |
| $ -497.63M | $ -492.89M | $ -128.47M | $ -315.59M | $ -282.56M | |
| $ -555.34M | $ -487.34M | $ -196.70M | $ -340.74M | $ -295.75M | |
| $ 42.90M | $ 64.64M | $ 51.51M | $ 14.77M | $ 4.59M | |
| $ -512.44M | $ -422.70M | $ -145.19M | $ -325.97M | $ -291.16M | |
| $ -512.54M | $ -422.77M | $ -145.22M | $ -325.99M | $ -290.58M | |
| Per Share Metrics | |||||
| Basic EPS | $ -2.97 | $ -2.57 | $ -1.06 | $ -2.60 | $ -2.39 |
| Diluted EPS | $ -2.97 | $ -2.57 | $ -1.06 | $ -2.60 | $ -2.39 |
| Weighted Average Shares Outstanding | 175.46M | 164.47M | 137.37M | 125.53M | 121.52M |
| Weighted Average Shares Outstanding (Diluted) | 175.46M | 164.47M | 137.37M | 125.53M | 121.52M |
Currency in USD
